Clinical trials · Illinois
Down Syndrome clinical trials in Illinois
We’re tracking 133 recruiting down syndrome studies with a site in Illinois — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT03047369Recruiting
Myelin brain disorder research biobank for samples and data
This study collects brain-related medical information and biological samples to help researchers better understand leukodystrophies and other white-matter brain disorders. It may help future diagnosis and treatments by building a valuable “biobank” of patient data and samples.
Chicago, IllinoisAges Any age - NCT03816319RecruitingPhase 1
TAK-243 for leukemia or MDS that has returned or not improved
This trial tests a new drug called TAK-243 in people with acute myeloid leukemia (AML) or myelodysplastic syndrome with increased blasts (MDS-IB) that has come back or hasn't gotten better after treatment. The goal is to see if TAK-243 can help when other options have stopped working.
Chicago, IllinoisAges 18 years+ - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
Chicago, IllinoisAges 1–40 - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Chicago, IllinoisAges 6–39 - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Chicago, IllinoisAges 18 years+ - NCT05432349Recruiting
Rett syndrome genetic registry for MECP2 changes
This trial is a registry that collects health and genetic information from people with Rett syndrome. It may help researchers better understand how MECP2 loss-of-function changes lead to symptoms and how to support patients.
Chicago, IllinoisAges birth–99 years - NCT06703073RecruitingPhase 2
Testing new treatments for acute respiratory distress syndrome (ARDS)
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
Evanston, IllinoisAges 18 years+ - NCT06701656RecruitingPhase 2
Testing bevacizumab for breathing problems from ARDS
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
Evanston, IllinoisAges 18 years+ - NCT06701682RecruitingPhase 2
Study of vilobelimab for moderate to severe ARDS
This trial tests a drug called vilobelimab for people with moderate or severe ARDS (a serious lung condition). It aims to find if this treatment can help improve breathing and outcomes.
Evanston, IllinoisAges 18 years+ - NCT06701669RecruitingPhase 2
Study of Paridiprubart for moderate to severe ARDS
This trial tests a new medicine called paridiprubart to see if it can help people with moderate or severe acute respiratory distress syndrome (ARDS), a serious lung condition. It may be an option if you have low oxygen levels and no known allergy to the drug.
Evanston, IllinoisAges 18 years+ - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Chicago, IllinoisAges 1–80 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Chicago, IllinoisAges Up to 22 years - NCT06465953RecruitingPhase 3
Ivosidenib vs azacitidine for IDH1-mutated MDS
This trial tests if the drug ivosidenib alone or azacitidine alone can help people with a specific type of MDS that has an IDH1 mutation. It is for people who have not had strong MDS treatments yet.
Chicago, IllinoisAges 18 years+ - NCT07519395RecruitingPhase 2
Camlipixant for abdominal symptoms in IBS-D and IBS-M
This study tests whether a new drug called camlipixant can reduce belly pain and other uncomfortable symptoms in people with irritable bowel syndrome that causes diarrhea or mixed symptoms. The trial compares camlipixant to a placebo (inactive pill) to see if it works better.
Morton, IllinoisAges 18–80 - NCT06914609RecruitingPhase 3
Study of ION582 for people with Angelman syndrome
This trial tests a new medicine called ION582 for people with Angelman syndrome. It aims to see if it can help with symptoms and is given as a lumbar puncture (spinal tap). You may be able to join if you have a genetic diagnosis of Angelman syndrome and are between 2 and 50 years old.
Chicago, IllinoisAges 2–50 - NCT07281079RecruitingPhase 3
Testing NNZ-2591 for children with Phelan-McDermid syndrome
This trial tests a new medicine, NNZ-2591, to see if it helps children with Phelan-McDermid syndrome. It is for children aged 3 to 12 who have a specific genetic change (SHANK3) and weigh at least 10 kg.
Chicago, IllinoisAges 3–12 - NCT06660394RecruitingPhase 3
LP352 for Dravet syndrome in children and adults
This study tests a new medicine called LP352 for children and adults with Dravet syndrome. It compares the study drug to a placebo (a pill with no medicine) to see if it helps reduce seizures.
Chicago, IllinoisAges 2–65 - NCT07555171Enrolling by invitation
Brain Wave Changes During Fenfluramine Treatment in Lennox-Gastaut Syndrome
This study tracks how brain wave patterns change when children and young adults with Lennox-Gastaut Syndrome (a severe seizure disorder) take fenfluramine, a medication that helps reduce drop seizures. Researchers will use EEG (brain wave recordings) to understand how this treatment affects the brain.
Chicago, IllinoisAges 2–35 - NCT05374824Recruiting
Palliative surgery versus more seizure medicines for Lennox-Gastaut
This trial compares two treatment approaches for children with Lennox-Gastaut syndrome: palliative (comfort-focused) surgery versus adding more anti-seizure medicines. It aims to see which option works better for seizure control and day-to-day well-being.
Chicago, IllinoisAges Up to 26 years - NCT06420297Enrolling by invitationPhase 3
Carbetocin nasal spray for Prader-Willi syndrome eating behaviors (open-label extension)
This is a long-term follow-up study for people who completed a previous study of carbetocin nasal spray for hyperphagia (extreme hunger) in Prader-Willi syndrome. The trial gives everyone the study drug openly to see if it continues to help manage eating behaviors over a longer period.
Chicago, IllinoisAges 5–30 - NCT07090889RecruitingPhase 1
Study of KM-023 for healthy volunteers and Olmsted syndrome patients
This trial tests a new medication, KM-023, first in healthy volunteers to check safety, and then in people with Olmsted syndrome (a rare skin condition causing thick, painful palms and soles). It aims to see if the drug is safe and helpful for those affected.
Chicago, IllinoisAges 18–55 - NCT06679855RecruitingPhase 3
Milrinone to prevent heart problems after PDA closure
This trial tests if giving milrinone before surgery to close a common heart vessel (PDA) can prevent heart issues in premature babies. It may help very premature infants who need surgery for a large PDA.
Chicago, IllinoisAges Up to 3 months - NCT07135050RecruitingPhase 1/Phase 2
Gene therapy study for Pitt Hopkins syndrome
This trial tests a new gene therapy called MZ-1866 for people with Pitt Hopkins syndrome. The therapy is given as a single injection into the fluid around the brain to help replace the missing or faulty TCF4 gene.
Chicago, IllinoisAges 2–25 - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Chicago, IllinoisAges 2–17
Down Syndrome trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting down syndrome studies listed above.
- Ann & Robert H. Lurie Children's Hospital of Chicago · 9 studies
- Endeavor Health · 4 studies
- OSF Saint Francis Medical Center · 4 studies
- University of Chicago · 4 studies
- Rush University Medical Center · 3 studies
- Northwestern University · 2 studies
- Advocate Children's Hospital - Oak Lawn
- Advocate Children's Hospital - Park Ridge
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Illinois?
- Yes. We're currently tracking 133 recruiting down syndrome studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.